Core Viewpoint - The announcement details the conversion results of the "Jianyou Convertible Bonds" and the changes in the company's share capital as of June 30, 2025, highlighting the low conversion rate and the significant amount of unconverted bonds [1][2][3]. Summary by Sections Conversion Situation - As of June 30, 2025, a total of RMB 719,000 worth of "Jianyou Convertible Bonds" has been converted into common shares, resulting in 18,035 shares, which represents 0.001% of the total shares before conversion [2][6]. - The total amount of "Jianyou Convertible Bonds" that has not been converted is RMB 502,464,000, accounting for 99.86% of the total issuance [3][6]. Convertible Bond Issuance Overview - The company issued 5,031,900 convertible bonds with a total value of RMB 503.19 million, with a maturity of 6 years, approved by the China Securities Regulatory Commission [4]. - The bonds were listed on the Shanghai Stock Exchange on May 22, 2020, under the code "113579" [4]. Conversion Price Adjustments - The initial conversion price was set at RMB 54.97 per share, which has been adjusted multiple times due to various corporate actions, with the latest adjustment bringing the price to RMB 24.34 per share as of June 5, 2025 [5].

Summary of Key Points Core Viewpoint - The announcement details the conversion results and share changes related to the "Jianyou Convertible Bonds" issued by Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd, highlighting the low conversion rate and the remaining unconverted bonds. Group 1: Conversion Status - As of June 30, 2025, a total of RMB 719,000 of "Jianyou Convertible Bonds" have been converted into ordinary shares, with RMB 7,000 of the bonds being repurchased [1][3] - The amount of unconverted "Jianyou Convertible Bonds" as of June 30, 2025, is RMB 502,464,000, which represents 99.86% of the total issuance [1][3] Group 2: Issuance Overview - The company issued 5,031,900 convertible bonds with a total value of RMB 5.0319 billion, with a maturity of 6 years, approved by the China Securities Regulatory Commission [1][2] - The bonds were listed on the Shanghai Stock Exchange starting from May 22, 2020, under the code "113579" [1][2] Group 3: Conversion Price Adjustments - The initial conversion price was set at RMB 54.97 per share, which has been adjusted multiple times due to various corporate actions, with the latest adjustment bringing the price down to RMB 24.34 per share effective from June 5, 2025 [2][3] Group 4: Share Capital Changes - The total share capital remained unchanged at 1,615,634,969 shares as of June 30, 2025, with no new shares issued from the conversion of the bonds [4]

Group 1 - The core viewpoint of the announcement is that the credit rating for Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd.'s convertible bonds remains unchanged at "AA" with a stable outlook [2][3]. - The previous rating for "Jianyou Convertible Bonds" was also "AA" with a stable outlook, indicating consistency in the company's creditworthiness [3]. - The tracking credit rating was conducted by United Credit Rating Co., Ltd., which assessed the company's business, management, and financial situation before issuing the report on June 27, 2025 [3]. Group 2 - The announcement confirms that the company's credit rating and the rating for the convertible bonds have not changed since the last assessment on June 26, 2024 [2][3]. - The report is available for further details on the Shanghai Stock Exchange website [3]. - The announcement was officially made by the board of directors of Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. on June 28, 2025 [5].

Group 1 - The company, Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd., has announced the results of the credit rating for its convertible bonds, maintaining a rating of "AA" for both the bonds and the company itself, with a stable outlook [1][2] - The previous tracking rating for the "Jianyou Convertible Bonds" was conducted on June 26, 2024, with the same ratings of "AA" and a stable outlook [1] - The credit rating agency, United Credit Rating Co., Ltd., performed a comprehensive analysis of the company's business, management, and financial conditions before issuing the 2025 tracking rating report on June 27, 2025 [2]

Core Viewpoint - Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. announces the conditional redemption of its convertible bonds due to the stock price falling below 70% of the conversion price for 30 consecutive trading days, triggering the redemption rights for bondholders [1][3]. Redemption Terms and Price - The conditional redemption clause allows bondholders to sell their convertible bonds back to the company at face value plus accrued interest if the stock price remains below 70% of the conversion price for 30 consecutive trading days during the last two interest years [1][4]. - The redemption price is set at 100.30 RMB per bond, which includes accrued interest and tax [3][5]. - The redemption period is from June 17, 2025, to June 23, 2025, with funds to be disbursed on June 26, 2025 [3][5]. Redemption Process - Bondholders can choose to redeem part or all of their unconverted bonds, and the redemption is not mandatory [4][5]. - The redemption application must be submitted through the Shanghai Stock Exchange trading system during the specified period [4][5]. - If the redemption results in the total face value of the convertible bonds being less than 30 million RMB, the bonds will continue to trade until the end of the redemption period [5]. Interest Calculation - The accrued interest is calculated using the formula: IA = B × i × t / 365, where B is the total face value of the bonds held, i is the annual coupon rate, and t is the number of days since the last interest payment [2][4]. - For the current interest year, the coupon rate is 2.0%, and the interest period is 55 days, resulting in an accrued interest of approximately 0.30 RMB per bond [4].

Group 1 - The company announced the conditional redemption of its convertible bonds, "Jianyou Convertible Bonds," allowing bondholders to sell their bonds back to the company at a price of 100.30 RMB per bond, including accrued interest [2][10][11] - The redemption period is set from June 17, 2025, to June 23, 2025, with funds to be disbursed on June 26, 2025 [3][11] - The bonds will stop converting into shares during the redemption period, but trading will continue [3][13] Group 2 - The company’s subsidiary, Meitheal Pharmaceuticals, received FDA approval for the production site transfer of Daunorubicin Hydrochloride Injection, which is used in the treatment of acute non-lymphocytic leukemia and acute lymphoblastic leukemia [15][16] - The approved product is expected to be launched in the U.S. market soon, which may positively impact the company's financial performance [18]

Core Points - The company announced the option for bondholders to sell back the "Jianyou Convertible Bonds" at a price of 100.30 RMB per bond, including accrued interest and tax [1][4] - The sell-back period is set from June 17, 2025, to June 23, 2025, with funds to be disbursed on June 26, 2025 [1][4] - During the sell-back period, the "Jianyou Convertible Bonds" will stop being convertible into shares [1][4] Summary of Key Details Sell-Back Terms - The sell-back price is determined based on the face value plus accrued interest, calculated as approximately 0.30 RMB per bond for the period from April 23, 2025, to June 17, 2025 [3][4] - The bondholders have the right to sell back all or part of their unconverted bonds, but this action is not mandatory [4][5] Conditions for Sell-Back - The sell-back option is activated if the company's stock price remains below 70% of the current conversion price for any consecutive thirty trading days during the last two interest years of the bonds [2][3] - If bondholders do not exercise their sell-back rights during the specified period, they will lose the option for the current interest year [2][3] Trading and Suspension - The "Jianyou Convertible Bonds" will continue to trade during the sell-back period but will not be convertible into shares [4][5] - If the total face value of the bonds in circulation falls below 30 million RMB due to the sell-back, trading will continue until the end of the sell-back period, after which the company will issue a related announcement [5]

Core Points - The company announced a cash dividend distribution of 0.1 yuan per share for the fiscal year 2024, totaling approximately 161.56 million yuan [2][4] - The dividend distribution plan was approved at the company's annual general meeting on May 20, 2025 [2][6] - The cash dividends will be distributed to all shareholders registered with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [3] Dividend Distribution Details - The total share capital before the distribution is 1,615,634,969 shares, with a cash dividend of 0.1 yuan per share [4] - Shareholders who have completed designated trading can receive their cash dividends on the distribution date at their designated securities firms [5] - For shareholders holding unrestricted circulating shares, the cash dividend will be distributed through the clearing system of the China Securities Depository and Clearing Corporation [5] Taxation Information - For individual shareholders holding unrestricted circulating shares for more than one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of 0.1 yuan per share [8] - For shares held for one year or less, the company will not withhold personal income tax at the time of distribution, but tax will be calculated based on the holding period when the shares are sold [8] - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, resulting in a net cash dividend of 0.09 yuan per share [10] Convertible Bond Adjustment - The company announced an adjustment to the conversion price of its convertible bonds, "Jianyou Convertible Bonds," effective June 5, 2025, changing from 24.44 yuan to 24.34 yuan per share [14][16] - The adjustment is based on the company's 2024 annual profit distribution plan, which includes a cash dividend distribution [15][16] - The conversion of the bonds will be suspended from May 28 to June 4, 2025, and will resume on June 5, 2025 [16]

Core Viewpoint - Nanjing Jianyou Biochemical Pharmaceutical Co., Ltd. has decided not to adjust the conversion price of its convertible bonds, despite triggering the downward adjustment clause due to stock prices falling below 90% of the current conversion price for 15 out of 30 trading days [2][7]. Group 1: Convertible Bond Details - The company issued 5,031,900 convertible bonds on April 23, 2020, with a total amount of 50.319 million yuan and a maturity of 6 years [3]. - The initial conversion price was set at 54.97 yuan per share, which has been adjusted to the latest price of 24.44 yuan per share [3][6]. - The conversion period for the bonds is from October 29, 2020, to April 22, 2026 [7]. Group 2: Price Adjustment History - The conversion price has undergone several adjustments due to various corporate actions, including stock incentive plans and profit distribution [4][5][6]. - Notable adjustments include a decrease from 54.97 yuan to 42.05 yuan due to the 2019 profit distribution and further adjustments down to 24.44 yuan as of July 8, 2024 [4][5][6]. Group 3: Decision on Price Adjustment - The board of directors held a meeting on May 23, 2025, and decided not to propose a downward adjustment of the conversion price, considering the long-term value of the company and the interests of all investors [2][7]. - The company will not propose any downward adjustment for the next six months, and any future decisions will be made after November 24, 2025, if the adjustment clause is triggered again [2][7].

Group 1 - The company will suspend the conversion of its convertible bonds, "Jianyou Convertible Bonds," from May 28, 2025, until the equity distribution registration date due to the implementation of the 2024 annual profit distribution [1][2][3] - The profit distribution plan approved by the shareholders' meeting includes a cash dividend of 1.00 yuan (including tax) for every 10 shares held, based on the total share capital registered on the equity distribution registration date [1][2] - The company will adjust the conversion price of the "Jianyou Convertible Bonds" in accordance with the terms outlined in the bond issuance prospectus following the equity distribution [2][3] Group 2 - The company will publish the relevant equity distribution implementation announcement and the convertible bond conversion price adjustment announcement on May 29, 2025 [2] - Holders of "Jianyou Convertible Bonds" must convert their bonds before May 27, 2025, to enjoy the equity distribution [3] - For detailed information regarding the "Jianyou Convertible Bonds," investors are directed to the bond issuance prospectus published on May 20, 2020 [3]